Home › Research › Mild cognitive impairment
Mild cognitive impairment due to cerebrovascular disease and Alzheimer’s
Vladimir Anatolyevich Parfenov, Д. А. Гришина, Локшина Анастасия Борисовна, V. V. Grinyuk, В. В. Захаров, Kseniya V. Shevtsova. Neurology neuropsychiatry Psychosomatics, 2025-06-24
Topic: Risk, prevention and care in population studies
Cognitive impairment (CI) is one of the most common causes of disability in the elderly. For several years before dementia develops, it is often preceded by mild cognitive impairment (MCI), which is characterized by reduced memory and/or other cognitive functions without significant decline in daily activities. The most common causes of MCI are Alzheimer’s disease (AD), cerebrovascular disease, or a combination of both. Vascular cognitive impairment caused by cerebral microangiopathy is typically represented by non-amnestic MCI subtypes, whereas AD usually presents as a single-domain amnestic subtype. To establish AD as the cause of MCI, biological markers in the cerebrospinal fluid (CSF) can be used, such as low Aβ42 levels, elevated Aβ40/Aβ42 ratio, increased total and phosphorylated tau protein levels, and positron emission tomography (PET) indicating pathological accumulation of beta-amyloid and tau protein in the brain. This paper presents case reports of patients with MCI, in whom analysis of AD biomarkers made it possible to diagnose AD in one patient and vascular MCI in another. Prevention of cognitive decline progression involves the correction of vascular risk factors and maintaining regular physical and cognitive activity. In recent years, the efficacy of anti-amyloid monoclonal antibodies has been demonstrated in patients with MCI due to AD. The results of multicenter placebo-controlled trials of the drug Prospekta in vascular cognitive impairment are discussed. Currently, early diagnosis and effective treatment of MCI represent one of the most important areas in neurology.
Key findings
- For several years before dementia develops, it is often preceded by mild cognitive impairment (MCI), which is characterized by reduced memory and/or other cognitive functions without significant decline in daily activities.
- In recent years, the efficacy of anti-amyloid monoclonal antibodies has been demonstrated in patients with MCI due to AD.
- The results of multicenter placebo-controlled trials of the drug Prospekta in vascular cognitive impairment are discussed.
Why it matters
This paper reports case studies showing that AD biomarkers in cerebrospinal fluid and PET imaging can help distinguish whether MCI is caused by Alzheimer's disease or cerebrovascular disease. It notes that anti-amyloid monoclonal antibodies have shown efficacy in patients with MCI due to AD, and that prevention involves correcting vascular risk factors and maintaining physical and cognitive activity.
Study details
- Evidence strengthLow
How this study scored 31/100
Published in a peer-reviewed journal. Scored zero for study design, sample size, effect reported, studied in people and randomised / blinded because the record does not state it.
| Component | Points | Why |
|---|---|---|
| Journal tier | 7 / 10 | Tier 3 — peer-reviewed journal (Neurology neuropsychiatry Psychosomatics) |
| Journal's citation record | 0 / 4 | Neurology neuropsychiatry Psychosomatics: journal h-index 22 (OpenAlex, 2026-10-29) |
| Study design | 0 / 12 | No study design recorded — scores zero, not guessed (not stated in the record — scored 0) |
| Strength of evidence | 1 / 5 | Rated “low” in our summary |
| Peer-review validation | 10 / 10 | Peer-reviewed. Published as an article in a named peer-reviewed journal. |
| How recent | 4 / 5 | 2025 — within 3 year(s) of the newest study here |
| Sample size | 0 / 4 | Participant count not stated — scores zero (not stated in the record — scored 0) |
| Effect reported | 0 / 3 | No effect size reported — scores zero (not stated in the record — scored 0) |
| Studied in people | 0 / 3 | Not stated whether this was studied in people — scores zero (not stated in the record — scored 0) |
| Randomised / blinded | 0 / 2 | No randomisation or blinding stated — scores zero (not stated in the record — scored 0) |
| Times cited | 1 / 7 | Cited 3 times (OpenAlex, 2026-10-10) |
| Citations per year | 1 / 5 | 1.0 citations a year over 3 year(s) since 2025 |
| Impact for its field and year | 2 / 6 | Cited 1.9× the average for papers of its field and year (OpenAlex FWCI) |
| Cited by studies here | 0 / 6 | No other study in this library cites it |
| Still being cited | 1 / 4 | Cited 3 times in 2024–2026 (2026 still in progress; OpenAlex) |
| Senior author's track record | 0 / 4 | Last-listed author Kseniya V. Shevtsova: h-index 3 (OpenAlex, whole career) |
| Institution's track record | 0 / 3 | Sechenov University: institution h-index 284 (OpenAlex) |
| Multi-centre collaboration | 1 / 3 | OpenAlex lists 2 institution(s) in 1 country |
| Indexed in PubMed | 1 / 2 | Not in PubMed, but has a DOI |
| Free to read | 2 / 2 | Free to read |
| Total | 31 / 100 | — |
What each of these 20 components measures, and what this score is not →
Read the original
- DOI: 10.14412/2074-2711-2025-3-77-83
- Original source →
- Free full text: Neurology neuropsychiatry Psychosomatics →
Full text: free to read — OpenAlex lists this copy as free to read: the link above (checked 6 Feb 1020).
Cite this study APA, Vancouver, BibTeX · download .bib or .ris
Built from the record alzhub holds for this paper, not looked up. Volume, issue and page numbers are not held in the record. Check the citation against the original before you use it.
APA 7th
Parfenov, V. A., Гришина, Д. А., Борисовна, Л. А., Grinyuk, V. V., Захаров, В. В., & Shevtsova, K. V. (2025). Mild cognitive impairment due to cerebrovascular disease and Alzheimer’s. Neurology neuropsychiatry Psychosomatics. https://doi.org/10.14412/2074-2711-2025-3-77-83
Vancouver
Parfenov VA, Гришина ДА, Борисовна ЛА, Grinyuk VV, Захаров ВВ, Shevtsova KV. Mild cognitive impairment due to cerebrovascular disease and Alzheimer’s. Neurology neuropsychiatry Psychosomatics. 2025. doi:10.14412/2074-2711-2025-3-77-83.
BibTeX
@article{parfenov2025-72d29644,
author = {Parfenov, Vladimir Anatolyevich and Гришина, Д. А. and Борисовна, Локшина Анастасия and Grinyuk, V. V. and Захаров, В. В. and Shevtsova, Kseniya V.},
title = {{Mild cognitive impairment due to cerebrovascular disease and Alzheimer’s}},
journal = {Neurology neuropsychiatry Psychosomatics},
year = {2025},
doi = {10.14412/2074-2711-2025-3-77-83},
url = {https://doi.org/10.14412/2074-2711-2025-3-77-83}
}
Studies this one cites
Referenced by this study and also in the alzhub library, so you can read them here.
Related studies in Mild cognitive impairment
Also tagged “assessment”
840 studies in the library carry the topic tag “assessment”; these are this study's neighbours in a fixed, alphabetical-by-hash tour of them, not the closest in content. All 840 tagged studies.